News | September 30, 2008

Abiomed's Impella 2.5 Device Now in 100 Leading U.S. Cardiac Hospitals

October 1, 2008 - Abiomed Inc. recently completed shipment of its Impella 2.5 Cardiac Assist Device to its 100th U.S. hospital following its June 2008 FDA clearance for partial circulatory support for periods up to six hours.

The intra-aortic balloon pump (IABP) also has 510(k) clearance and approximately 124,000 are used each year in the U.S. Abiomed is currently conducting two U.S. pivotal studies comparing the Impella 2.5 to the IABP (Protect II for high-risk percutaneous coronary intervention, or PCI; and Recover II for acute myocardial infarction, AMI). There are an estimated 60,000 annual high-risk PCI patients and 100,000 AMI anterior infarct patients annually in the U.S.

The Impella 2.5 is inserted percutaneously in the catheterization laboratory via the femoral artery into the left ventricle. Up to 2.5 liters of blood per minute are delivered by the pump from the left ventricle into the ascending aorta, providing the heart with active support in critical situations.
The Impella 2.5 is now approved in more than 40 countries, including in Europe under the CE Mark. The Impella platform has been used to treat more than 1,500 patients outside the U.S. and has been the subject of more than 50 peer-reviewed publications, the company said.

For more information:

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init